Quanterix Stock Soars 14% After Sales Recover — Alzheimer's Testing Still Brings Little Revenue
Revenue rose 6.3% from the second quarter, while management expects to end the year debt-free with about $70 million in cash.
Quanterix, which sells instruments and tests that detect proteins for research and diagnostics, soared 13.64% to $3.29 in Monday trading, as of 10:25 a.m. ET, adding $18 million in market value. The rally followed Monday's results release showing a 6.3% revenue increase from the second quarter, though management cautioned that Alzheimer's testing still generates relatively little revenue.
Sales Recover, Losses Persist
Third-quarter revenue totaled $35.0 million. Quanterix also reported a net loss of $21.6 million.
Everett Cunningham, Quanterix's president and CEO, described the sales improvement as a "first step in restoring growth."
Quanterix tightened its annual sales forecast to $142–146 million. Management expects the company to end the year without debt and with approximately $70 million in cash.
More Alzheimer's Tests, Little Revenue
On Monday's earnings call, the chief financial officer cautioned that revenue from Alzheimer's testing remains relatively immaterial, even though test volume doubled. The testing increase has yet to become a substantial revenue contributor.
Quanterix's Accelerator Laboratory in Bedford, Massachusetts, offers contract research and clinical laboratory testing, including blood tests used by healthcare providers to evaluate Alzheimer's disease and other neurological conditions.
The broader business sells instruments, consumables, test kits, software, extended warranties and service contracts. Its Simoa and Spatial Biology platforms help customers measure tiny protein concentrations in blood and other fluids and locate proteins and cells in tissue.
Customers include research laboratories, academic institutions, contract research organizations and biopharmaceutical companies worldwide. Its annual report for the fiscal year ended December 31, 2025, put the installed instrument base at over 2,500.
A Rally Against A Steep Slide
At Friday's close, Quanterix shares were down 54% for the year, compared with an 8% gain for the S&P 500. The stock had also fallen 16% over the previous month.
In Monday trading, shares were on pace for their biggest one-day gain since June 26. Quanterix's market value stood at about $156 million in Monday trading, as of 10:25 a.m. ET.
Quanterix's next earnings report is scheduled for Wednesday in January.
Sources
- Dawn Lim - Nextgov/FCW — nextgov.com
- North American Morning Briefing: Stock Futures Up But Nvidia Slides Premarket on Huang Probe -2- | Morningstar — morningstar.com
- Quanterix Releases Financial Results for the Third Quarter of 2026 — businesswire.com
- The company's filing (Quanterix) — SEC filing
- Quanterix — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR